Onco Wiki / Biomarqueur

Hormone anti-müllerienne (réserve ovarienne — horaire BSO dans les transporteurs BRCA)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDBIO-AMH-OVARIAN-RESERVE
TypeBiomarqueur
Alias
AMHHormone antimüllèreMISMatière inhibante de la mullerieАнтимюллерів гормон (оваріальний резерв — час BSO у носіїв BRCA)
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesDIS-OVARIAN
SourcesSRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025

Données biomarqueurs

Type de biomarqueurserum_marker
Mesure
MéthodeImmunodosage sérique (ECLIA, CLIA); cycle-jour indépendant
Unitésng/mL (ou pmol/L; conversion 1 ng /mL ‡ 7,14 pmol /L)
Échelle type
  • 0.5
  • 5.0
Biomarqueurs connexesAucune déclaration

Notes

Granulosa-cell-derived hormone reflecting primordial follicle pool; best single biomarker of ovarian reserve. Adjunct to risk-reducing bilateral salpingo-oophorectomy (RRSO) counseling in BRCA1/BRCA2 germline carriers and other HBOC syndromes (BRIP1, RAD51C, RAD51D, PALB2). NCCN 2025 (Genetic/Familial High-Risk: Breast/Ovarian): BRCA1 RRSO recommended at age 35-40 (after completion of childbearing); BRCA2 at age 40-45. AMH supports timing discussion — declining AMH (<1.0 ng/mL = diminished reserve) helps quantify remaining reproductive window and informs fertility-preservation referral (oocyte/embryo cryopreservation) before RRSO. NOT a screening test for ovarian cancer (CA-125 + TVUS combination has been evaluated and is NOT recommended for screening per UKCTOCS — no mortality benefit). Used in pediatric ovarian function monitoring after gonadotoxic chemotherapy (childhood cancer survivors). Falsely elevated in granulosa-cell tumors and PCOS; falsely suppressed by hormonal contraceptives. STUB pending two-Co-Lead signoff.

Utilisé par

Pertinence thérapeutique